GYRE THERAPEUTICS INC (GYRE) Stock Price, Quote, News and Overview
NASDAQ:GYRE - Nasdaq - US4037831033 - Common Stock - Currency: USD
GYRE Quote, Performance and Key Statistics
8.85
+0.14 (+1.61%)
The current stock price of GYRE is 8.85 USD. In the past month the price increased by 22.24%. In the past year, price decreased by -40.28%.
GYRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.73B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
| ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
| NTRA | NATERA INC | N/A | 21.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
| BIIB | BIOGEN INC | 7.41 | 17.17B |
Related stock screener links
About GYRE
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 574 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Company Info
GYRE THERAPEUTICS INC
12770 High Bluff Drive, Suite 150
San Diego CALIFORNIA US
Employees: 579
Phone: 16199493681
GYRE THERAPEUTICS INC / GYRE FAQ
What is the stock price of GYRE THERAPEUTICS INC today?
The current stock price of GYRE is 8.85 USD. The price increased by 1.61% in the last trading session.
What is the ticker symbol for GYRE THERAPEUTICS INC stock?
The exchange symbol of GYRE THERAPEUTICS INC is GYRE and it is listed on the Nasdaq exchange.
On which exchange is GYRE stock listed?
GYRE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GYRE THERAPEUTICS INC stock?
7 analysts have analysed GYRE and the average price target is 20.4 USD. This implies a price increase of 130.51% is expected in the next year compared to the current price of 8.85. Check the GYRE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GYRE THERAPEUTICS INC worth?
GYRE THERAPEUTICS INC (GYRE) has a market capitalization of 829.60M USD. This makes GYRE a Small Cap stock.
How many employees does GYRE THERAPEUTICS INC have?
GYRE THERAPEUTICS INC (GYRE) currently has 579 employees.
What are the support and resistance levels for GYRE THERAPEUTICS INC (GYRE) stock?
GYRE THERAPEUTICS INC (GYRE) has a support level at 8.7 and a resistance level at 9.18. Check the full technical report for a detailed analysis of GYRE support and resistance levels.
Is GYRE THERAPEUTICS INC (GYRE) expected to grow?
The Revenue of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -84.37% in the next year. Check the estimates tab for more information on the GYRE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GYRE THERAPEUTICS INC (GYRE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GYRE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GYRE, evaluating the profitability, health, valuation and growth aspects
- GYRE THERAPEUTICS INC (GYRE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GYRE THERAPEUTICS INC (GYRE) Sales and EPS estimates to see what analysts future expectations are.
- GYRE THERAPEUTICS INC (GYRE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GYRE THERAPEUTICS INC (GYRE) Insider and Institutional Ownership to learn about the owners and their transactions.
- GYRE THERAPEUTICS INC (GYRE) Stock Chart to make your own analysis
- GYRE THERAPEUTICS INC (GYRE) Latest news and press-releases to stay up to date.
Does GYRE THERAPEUTICS INC (GYRE) stock pay dividends?
GYRE does not pay a dividend.
When does GYRE THERAPEUTICS INC (GYRE) report earnings?
GYRE THERAPEUTICS INC (GYRE) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of GYRE THERAPEUTICS INC (GYRE)?
GYRE THERAPEUTICS INC (GYRE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.87).
What is the Short Interest ratio of GYRE THERAPEUTICS INC (GYRE) stock?
The outstanding short interest for GYRE THERAPEUTICS INC (GYRE) is 17.77% of its float. Check the ownership tab for more information on the GYRE short interest.
GYRE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GYRE. When comparing the yearly performance of all stocks, GYRE is a bad performer in the overall market: 86.26% of all stocks are doing better.
GYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GYRE. While GYRE has a great health rating, its profitability is only average at the moment.
GYRE Financial Highlights
Over the last trailing twelve months GYRE reported a non-GAAP Earnings per Share(EPS) of -2.87. The EPS decreased by -1.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.43% | ||
| ROA | 9.64% | ||
| ROE | 19.09% | ||
| Debt/Equity | 0 |
GYRE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to GYRE. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 590.45% and a revenue growth -84.37% for GYRE